This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Pulmonary Hypertension
and you are
under 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This study was designed to investigate treatment of postoperative pulmonary hypertension by iloprost inhalation in children with congenital heart defects. It was a controlled single-blind randomized multi-center prospective study in order to explore the efficacy of this method in the treatment and prevention of pediatric pulmonary hypertension after corrective open-heart surgery for congenital heart defects.

Provided treatments

  • Drug: iloprost nebuliser solution
  • Drug: distilled water
Tris trial is registered with FDA with number: NCT01598441. The sponsor of the trial is Shanghai Jiao Tong University School of Medicine and it is looking for 8 volunteers for the current phase.
Official trial title:
Multi-centre, Randomized Study of Iloprost Inhaled in Preventing and Treating Reactive Pulmonary Hypertension (RPH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Diseases (CHD)